Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
SOUTH SAN FRANCISCO, Calif., Jan. 21, 2016 -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, announced today that it has joined over 80 pharmaceutical, biotechnology, and diagnostics companies in drafting and signing the Declaration on Combating Antimicrobial Resistance. The Declaration – which highlights the continued increase of bacterial resistance to antibiotics and the urgent need to develop new, innovative drugs – is a call to action, outlining specific initiatives that governments and industry can implement in a collaborative effort to further address the threat of Antimicrobial Resistance (AMR). This initiative further demonstrates Achaogen’s commitment to economic, regulatory, and reimbursement reform toward establishing a sustainable solution that incentivizes the development and commercialization of novel antibiotics addressing the unmet need of treating drug resistant infections.
“Achaogen is focused on the discovery and development of new antibacterials to treat multi-drug resistant, gram-negative infections and is committed to participating in the coordinated global action required to address the public health threat posed by AMR,” said Kenneth Hillan, Achaogen’s Chief Executive Officer. “We applaud the efforts of Lord O’Neill’s Review on AMR and are pleased to support this Declaration and the call for collective global measures to overcome the barriers to the development and commercialization of life-saving antibiotics.”
The Declaration, along with a complete list of signatories, is available at the Review on AMR website at www.amr-review.org/industry-declaration.
About Achaogen
Achaogen is a clinical-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterials to treat MDR gram-negative infections. Achaogen is developing plazomicin, Achaogen’s lead product candidate, for the treatment of serious urinary tract, lung, and bloodstream infections due to Enterobacteriaceae, including CRE. Achaogen’s plazomicin program is funded in part with a contract from the Biomedical Advanced Research and Development Authority. Plazomicin is the first clinical candidate from Achaogen’s gram-negative antibiotic discovery engine, and Achaogen has other programs in early and late preclinical stages focused on other MDR gram-negative infections. For more information, please visit www.achaogen.com.
Contact Candice Knoll Blueprint Life Science Group 415.375.3340 Ext. 4 [email protected]
